NFKB1 and irritable bowel syndrome: These findings are in strong agreement with the study by Khodabakhsh et al. who reported that Montelukast treatment suppressed NF-κB expression and reduced pro-inflammatory cytokines in IBS rats, highlighting the canonical role of NF-κB signaling in stress-induced gut inflammation [27].